Gilead: Near-Term Drug Filings Planned, But HIV Pressure Persists
Gilead expects to file for a new triple combination, Truvada plus Johnson & Johnson's TMC278, later this year, to extend the life of its HIV franchise.
Gilead expects to file for a new triple combination, Truvada plus Johnson & Johnson's TMC278, later this year, to extend the life of its HIV franchise.